François Girodon
Centre National de la Recherche Scientifique · 210 works · 5,525 citations · h-index 42
Top works
- The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera
- Leukemic blasts in transformed JAK2-V617F–positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.
- Impact of Trace Elements and Vitamin Supplementation on Immunity and Infections in Institutionalized Elderly Patients
- A prognostic model to predict survival in 867 World Health Organization–defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment
- Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis.
- Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations
- Effect of a two-year supplementation with low doses of antioxidant vitamins and/or minerals in elderly subjects on levels of nutrients and antioxidant defense parameters.
- Genetic Basis of Congenital Erythrocytosis: Mutation Update and Online Databases
- Usefulness of the eosin‐5′‐maleimide cytometric method as a first‐line screening test for the diagnosis of hereditary spherocytosis: comparison with ektacytometry and protein electrophoresis
- Effect of Micronutrient Supplementation on Infection in Institutionalized Elderly Subjects: A Controlled Trial
- Latent myeloproliferative disorder revealed by the JAK2-V617F mutation and endogenous megakaryocytic colonies in patients with splanchnic vein thrombosis
- Age, JAK2V617F and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis
- Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F
- Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Cote d'Or (Burgundy, France)
- Increase therapy-related leukemia secondary to breast cancer
- The ‘GGCC’ haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera
- Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis
- Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution
- Standardization and comparison of endogenous erythroid colony assays performed with bone marrow or blood progenitors for the diagnosis of polycythemia vera
- Concordance of assays designed for the quantification of JAK2V617F: a multicenter study